FDA approves Perrigo’s NDA for testosterone gel 1%

Download PDF Copy

Feb 5 2013

Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel® 1%.

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."

SOURCE Perrigo

Posted in: Men's Health News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Study highlights menopause-related vocal changes in women

Creatine in your diet may benefit your digestive system

Study reveals how SARS-CoV-2 hijacks testicular lipid metabolism to replicate

Why protein powders can secretly cause doping bans

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

New ASPIRE trial tests chemotherapy combination for advanced prostate cancer

Testosterone fails to influence risk-taking or fairness in men

Inherited DNA changes can cause hormone imbalance in women with polycystic ovary syndrome

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.